Twitter Beğeni Hilesi

“I think inclusivity and collaboration are a natural, inevitable part of drug discovery… we need input from so many areas of expertise.” -Muneto Mogi, Head of Global Medicinal Chemistry Find out how your skills can contribute to developing innovative medicines for patients.

For Shiva Malek, breakthrough drug discovery hinges on three key elements: “Fundamental research, technological innovation and sticking with the tough problem.” Read more in a recent interview: live.novartis.com/article/scienc…

After one door closed on a promising compound with the potential to inhibit part of the immune system linked to multiple diseases, collaboration among chemists, disease researchers and clinicians ensured the drug found a path forward to patients.

The science suggested a molecule might treat multiple diseases caused by the same problem in the immune system. Faced with choosing which disease to pursue first, our researchers boldly launched several studies in parallel hoping to help more patients faster.

A Nature Chemical Biology News & Views describes recently published research from Broad Institute and Novartis that uses DNA-encoded libraries (DELs) to identify proximity-inducing small molecules for drug development. novartis.social/6010979bu

Nature research paper: Predicting crystal form stability under real-world conditions go.nature.com/3MXxv4z

Novartis and CKD Pharmaceutical Corp have entered into a licensing agreement to develop and commercialize an experimental small molecule to explore in certain cardiovascular diseases.

Novartis researchers used single cell RNA sequencing from human cortical brain organoid models and identified a novel link between the 16p11.2 variant and RBFOX1 both of which are implicated in neurodevelopmental diseases, including autism. Learn more: go.novartis.social/3ugWWr5

Building on our leadership in CAR-T cell therapy innovation, Novartis has entered into a license agreement with Legend Biotech to advance the development of certain CAR-T cell therapies targeting DLL3, a ligand highly expressed in some malignancies.

Novartis has expanded its collaboration with Voyager Therapeutics to develop potential gene therapies for people with severe neurological diseases. linkedin.com/posts/voyager-…

I’m excited to share that we’re entering a strategic research collaboration with Isomorphic Labs to use state-of-the-art #AI technologies—including the next-gen model of AlphaFold—to discover novel small molecule therapeutics for select biological targets. storage.googleapis.com/isomorphiclabs…

Novartis has exercised its option to acquire IFM Due, advancing a collaboration started in 2019 to innovate novel STING antagonists with the potential to address unmet needs in inflammation-driven diseases. novartis.social/6017ci8ZW

Novartis has entered into a transaction with Arvinas, including a global license agreement for the development and commercialization of an androgen receptor (AR) degrader which is in clinical development for prostate cancer.

Yesterday, Novartis and Medicines for Malaria Venture (MMV) announced positive data from the CALINA study exploring a potential medicine formulated for the smallest babies with #malaria, for whom there is currently no evidence-based treatment.

Novartis, PeptiDream have entered into an agreement to expand their discovery collaboration aimed at identifying novel peptides for potential use in radioligand therapy and other contexts businesswire.com/news/home/2024…

In APL Bioengineering, Novartis researchers unveil a new device that enables high-throughput screening of stretched cells to better understand how they respond under mechanical stress and inform drug discovery. #mechanobiology

Our researchers share a new approach for the potential treatment of #sicklecelldisease: using molecular glue degraders to break down a novel protein that suppresses fetal hemoglobin levels. Read their paper in Science Magazine

Applications are being accepted for the Novartis Data Science Innovation Fellowship Program. If you are a recent PhD grad with a passion for #datascience & #AI and are interested in a career helping patients by advancing #drugdiscovery, apply by July 29.

Novartis, Dren Bio sign collaboration agreement to discover, advance antibody-based immune cell engagers for certain cancers, building on Novartis efforts to explore a range of modalities and approaches to bring transformative therapies forward for patients.

Novartis and Versant Ventures launch Borealis Biosciences, a discovery-stage biotech focused on developing next-generation RNA medicines for kidney diseases. go.novartis.social/4dxm92o